Corifollitropin alfa. Efficacy, safety and convenience for doctor and patient

Abstract

The efficacy and safety of the only existing corifollitropin alpha drug was compared with recombinant follicle stimulating hormone (rFSH) preparations administered for the purpose of stimulating multi-follicular growth under in vitro fertilization/intracytoplasmic sperm injection programmes. According to numerous sources, the efficacy in terms of live birth rates, clinical and ongoing pregnancy among female patients receiving corifollitropin alpha and those receiving rFSH during the first 7 days of stimulation was comparable. There were no statistical differences between the corifollitropin alfa and rFSH groups in terms of the incidence of ectopic and multiple pregnancy, risk of OHSS, embryonal/fetal malformations. The rate of antibody formation to corifollitropinu alpha was not clinically relevant. There were statistical differences in ovarian response between the groups of patients receiving corifollitropin alpha and patients taking rFSH reflected in a higher number of cumulus oocyte complexes in the corifollitropin alpha group. Patients demonstrated higher satisfaction after receiving corifollitropin alpha compared to rFSH due to a lower number of injections required.